| Phase 12 trials |
|
Phase 1
|
NCT07693426 |
Jul 2026 → Apr 2027 expected |
— |
Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. |
Not yet recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT07518121 |
Jun → Aug 2026 overdue |
type 2 diabetes mellitus |
Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. |
Not yet recruiting
|
No outcome recorded
|
| Phase 22 trials |
|
Phase 2
|
NCT07114419 |
Aug 2025 → Jun 2026 overdue |
obesity disorder |
Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06732960 |
Apr → Nov 2024 |
obesity disorder |
Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. |
Completed
|
No outcome recorded
|
| Phase 2/32 trials |
|
Phase 2/3
|
NCT06921486 |
Mar 2025 → Aug 2026 overdue |
obesity disorder |
Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. |
Active not recruiting
|
No outcome recorded
|
|
Phase 2/3
|
NCT04998032 |
Oct 2021 → Jun 2023 |
type 2 diabetes mellitus |
Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. |
Completed
|
No outcome recorded
|
| Phase 31 trial |
|
Phase 3
|
NCT06900075 |
Jul 2025 → Jan 2026 overdue |
type 2 diabetes mellitus |
Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. |
Not yet recruiting
|
No outcome recorded
|
| Phase 41 trial |
|
Phase 4
|
NCT07163650 |
Sep 2025 → Nov 2026 expected |
obesity disorder |
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
Recruiting
|
No outcome recorded
|